The revenue miss and widening losses are near-term negatives, but the accelerating commercial adoption (robotic catheter revenue, first GenesisX sale) and clear guidance for recurring revenue growth to $7-8M in Q3-Q4 suggest a potential inflection. Traders should watch for manufacturing ramp updates and further system orders; the path to cash flow profitability in H1 2027 is key for sentiment.
Price Chart
Executive Summary
Stereotaxis reported Q2 2026 revenue of $7.7M, missing consensus of $8.3M, and EPS of -$0.06, missing consensus of -$0.05. Despite the headline miss, robotic catheter revenue surpassed $1M (up 270% sequentially), the first GenesisX system purchase was secured, and guidance calls for recurring revenue growth to $7M in Q3 and $8M in Q4, with cash flow profitability targeted by H1 2027. The stock will likely react to the revenue miss and continued operating losses, but the commercial inflection narrative and forward guidance provide a counterbalance.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $7.7M vs consensus $8.3M (miss)
- Q2 2026 EPS -$0.06 vs consensus -$0.05 (miss)
- Robotic catheter revenue exceeded $1M, up 270% sequentially
- First GenesisX robotic system purchase by a US hospital, installation expected fall 2026
- Recurring revenue grew to $6.2M from $5.8M YoY
- Gross margin 58%, recurring revenue gross margin 66%
- Operating loss widened to -$4.6M from -$4.0M YoY
- Net loss attributable to common stockholders -$4.8M vs -$4.1M YoY
- Cash and equivalents $10.5M, no debt
- Guidance: Q3 recurring revenue ~$7M, Q4 ~$8M; system revenue ~$3M per quarter; cash flow profitability targeted H1 2027
- Completed acquisition of Robocath
Financial Impact
Revenue miss of ~$0.6M (7.3% below consensus); net loss widened by ~$0.6M YoY; cash burn continues at ~$3.7M per quarter
Risk Factors
- Revenue miss and continued operating losses may pressure near-term stock price
- Cash burn rate of ~$3.7M/quarter with only $10.5M cash could necessitate dilution before profitability
- Dependence on MAGiC catheter manufacturing ramp to meet recurring revenue guidance
- Integration risk from Robocath acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343137 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $1.39 $1.18 | ▼ −15.11% | ▼ −13.92% | $0.9900 (−28.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 11, 2026 10w ago | Press Release | $1.40 $1.30 | ▼ −7.14% | ▼ −5.25% | $0.9900 (−29.29%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▲ +16.36% | ▲ +19.98% | $0.9900 (+40.00%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▼ −16.36% | ▼ −19.98% | $0.9900 (−40.00%) |
Jul 9, 2026 15w ago | 8-K | $1.74 $1.36 | ▼ −21.84% | ▼ −24.08% | $0.9900 (−43.10%) |
May 12, 2026 23w ago | 8-K | $1.85 $1.82 | ▲ +1.62% | ▲ +1.01% | $0.9900 (+46.49%) |
May 12, 2026 23w ago | Press Release | $1.85 $1.82 | ▼ −1.62% | ▼ −1.01% | $0.9900 (−46.49%) |
Apr 21, 2026 26w ago | Press Release | $1.92 $1.78 | ▼ −7.29% | ▼ −12.21% | $0.9900 (−48.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers